KRAS ACTIVATING MUTATION
Clinical trials for KRAS ACTIVATING MUTATION explained in plain language.
Never miss a new study
Get alerted when new KRAS ACTIVATING MUTATION trials appear
Sign up with your email to follow new studies for KRAS ACTIVATING MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Four-Drug attack on deadly pancreatic cancer enters human testing
Disease control OngoingThis study is testing a new combination of four drugs for people with metastatic pancreatic cancer who have not yet received any treatment. The main goals are to find the safest and most effective dose of the new drug pair (avutometinib and defactinib) when added to two standard …
Matched conditions: KRAS ACTIVATING MUTATION
Phase: PHASE1, PHASE2 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
New hope for Tough-to-Treat lung cancer: testing a powerful drug cocktail
Disease control OngoingThis study is testing a new combination of two or three drugs for people with a specific type of lung cancer (KRAS G12C Non-Small Cell Lung Cancer). It aims to see if the combination is safe and effective, especially for patients whose cancer has progressed after previous treatme…
Matched conditions: KRAS ACTIVATING MUTATION
Phase: PHASE1, PHASE2 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC